We are Hiring

Director,

Global Medical Communications

Director, Global Medical Communications

Bicara Therapeutics is seeking an experienced Director of Global Medical Communications to oversee publication strategy and execution for oncology programs. Reporting to the Senior Vice President, Clinical & Medical Affairs, this individual will drive the development of clear, consistent, and scientifically rigorous communications that support Bicara’s clinical and medical objectives.

This position is well-suited for a detail-oriented professional who excels in cross-functional collaboration, manages complex deliverables under tight timelines, and ensures that data are accurately and effectively communicated to the medical and scientific community.

Apply Now
Dyne

Position Responsibilities

  • Lead the global publication strategy and execution for assigned oncology assets, including abstracts, posters, manuscripts, oral presentations, and other external communications.
  • Collaborate with Clinical Development, Medical Affairs, and senior leadership to define scientific messages and ensure consistency across all communication platforms.
  • Serve as publications lead on cross-functional teams, coordinating with Clinical, Regulatory, Commercial, and Medical Affairs to align on strategy, timelines, and content accuracy.
  • Develop and implement publication processes and governance models in accordance with ICMJE, GPP, and internal compliance standards.
  • Manage publication plans, timelines, and deliverables using internal tools; ensure transparency and accountability across stakeholders.
  • Provide scientific oversight and editorial review of content to ensure accuracy, clarity, and data integrity.
  • Manage internal writers and external vendors to ensure timely, high-quality, and cost-effective deliverables.
  • Partner with Clinical and Finance teams to forecast resource needs, manage publication budgets, and monitor spend against plan.
  • Support the development of scientific platforms, slide decks, congress materials, and medical training tools in collaboration with Medical Affairs.
  • Engage with investigators and key opinion leaders on authorship planning, data interpretation, and publication development.
  • Maintain accurate and compliant documentation of publication activities and ensure audit readiness.
Apply Now

Preferred Qualifications

Apply Now

Know About

About
Bicara

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.

Product
Pipeline

Bicara Therapeutics is advancing a focused pipeline built around its proprietary bifunctional antibody platform, designed to target tumor-driving pathways while modulating the immune microenvironment. The lead candidate, BCA101 (ficerafusp alfa), is a first-in-class EGFR-targeting and TGF-β–trapping antibody currently in a pivotal Phase 2/3 trial (FORTIFI-HN01) for first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), following promising Phase 1/1b results.

Beyond BCA101, Bicara’s pipeline includes BCA-356, a preclinical bifunctional molecule targeting CAIX and IL-12 to activate localized immune responses. The company is also advancing early-stage discovery programs, including BCA-202, BCA-300, and BCA-400, which reflect its commitment to next-generation, dual-function biologics for solid tumors.

Notable
Articles

Advancing life sciences with expert talent.

(888) 342-2066

Christina@TheElleGrp.com

www.TheElleGrp.com

The Elle Group

The Elle Group

Christina Cagle
Christina Cagle

I am a dedicated advocate for scientific innovation, serving as a strategic partner and collaborator. My mission is to bridge vision with execution, driving breakthroughs that transform lives. Let’s work together to shape a future where science fuels progress and creates a lasting impact.

Christina Cagle, Founder The Elle Group

© 2024 The Elle Group. All Rights Reserved.